Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Divesiran - Silence Therapeutics

Next Previous
Drug Profile

Divesiran - Silence Therapeutics

Alternative Names: SLN-124

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intradigm Corporation
  • Developer Silence Therapeutics
  • Class Antineoplastics; Hexosamines; Small interfering RNA
  • Mechanism of Action RNA interference; TMPRSS6 protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Myelodysplastic syndromes; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Polycythaemia vera
  • Phase I Myelodysplastic syndromes
  • No development reported Haemochromatosis; Iron overload
  • Discontinued Beta-thalassaemia

Most Recent Events

  • 15 Jun 2025 Updated efficacy data from a phase I/II trial in Polycythaemia vera released by Silence Therapeutics
  • 09 Dec 2024 Divesiran - Silence Therapeutics receives Fast Track designation for Polycythaemia vera [SC,Injection] in USA
  • 09 Dec 2024 Updated efficacy and adverse event data from a phase I/II trial in Polycythemia released by Silence Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top